Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective ‘ablate‐and‐resect’ study

Objective To assess histopathological outcomes, as well as feasibility and safety of targeted microwave ablation (TMA) via the Trinity® system (KOELIS, La Tronche, France). Patients and methods Prospective, single‐institution, interventional Phase IIa study with an ‘ablate‐and‐resect’ design. In all...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BJU international 2024-08, Vol.134 (2), p.258-267
Hauptverfasser: Peltier, Alexandre, Velthoven, Roland, Baudewyns, Arthur, Assenmacher, Grégoire, Lemort, Marc, Lefebvre, Yolene, Sirtaine, Nicolas, Diamand, Romain
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 267
container_issue 2
container_start_page 258
container_title BJU international
container_volume 134
creator Peltier, Alexandre
Velthoven, Roland
Baudewyns, Arthur
Assenmacher, Grégoire
Lemort, Marc
Lefebvre, Yolene
Sirtaine, Nicolas
Diamand, Romain
description Objective To assess histopathological outcomes, as well as feasibility and safety of targeted microwave ablation (TMA) via the Trinity® system (KOELIS, La Tronche, France). Patients and methods Prospective, single‐institution, interventional Phase IIa study with an ‘ablate‐and‐resect’ design. In all, 11 patients diagnosed with localised prostate cancer (PCa) underwent TMA via the Trinity system under conscious sedation in an outpatient setting using a single transrectal TATO® 18‐G antenna with different treatment regimens. Magnetic resonance imaging (MRI) and robot‐assisted radical prostatectomy (RARP) were conducted at 7 days and 1 month after TMA, respectively. Nine patients received RARP, and two patients chose to withdraw their consent following TMA. These men chose an active surveillance protocol upon confirmation of a low‐risk prostate cancer diagnosis. Functional outcomes and adverse events were evaluated at baseline and follow‐up visits using validated questionnaires. Prostate volumetry and confirmation of necrosis were carried out through MRI and whole‐mount histopathological examination. Results The TMA was successfully executed, and all patients were discharged on the same day. No severe adverse events (Common Terminology Criteria for Adverse Events Grade ≥3) were reported at the 7‐day and 1‐month follow‐up visits. Additionally, no declines were observed in urinary, sexual and ejaculation functional outcomes. T1‐weighted MRI revealed clear and well‐defined ablation zones. The RARP was executed without difficulty, particularly during the dissection of the posterior plane. As a result, no intraoperative complications were encountered. Histopathological assessment on surgical specimens confirmed the absence of viable cells, indicating complete necrosis of the ablative zone if a power intensity >10 W was used during TMA. Ablation zone volumetry revealed no notable distinctions between the three‐dimensional segmentation of the virtual ablation zone at TMA (median volume: 2 mL) and MRI (median volume: 1.923 mL). Conversely, a significant reduction was noted in the surgical specimen (median volume: 0.221 mL). Conclusions Targeted microwave ablation via the Trinity system for localised PCa treatment proves to be a secure and feasible procedure, with complete necrosis evidence within the ablation zone on surgical specimens.
doi_str_mv 10.1111/bju.16385
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3054841643</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3081881682</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3135-4e6324e699447b832142b8e4a4094206047a98aa88b4c491e324a555325ab64b3</originalsourceid><addsrcrecordid>eNp1kcFOGzEQhi1URCD0wAuglXoJhwR7Pet4ubURtFRROZBIva3GmwnaaLMb7F1QbnmEHtvXy5N0SKAHpPowtjzf_JqZX4gzJQeKz6VbtANltE0OxLECA31Q8ueHt7dMTUechLCQkj9MciQ62g4hBmWORTlB_0ANzaJlkfv6GZ8oQldiU9RVNK99tPJ1aLChKMcqJx_1bu7uJ7c_rpW7uIpwl15R3hRct9383pXSdvMLqxlHT4Fz282fKDTtbH0qDudYBvr4enfF9OZ6MvrWH999vR19HvdzrXTSBzI65pCmAENndawgdpYAeRSIpZEwxNQiWusgh1QR05gkiY4TdAac7oreXpe7e2wpNNmyCDmVJVZUtyHTMgHL44Nm9NM7dFG3vuLumLLKWmVszNTFnuIVheBpnq18sUS_zpTMXizI2IJsZwGz56-KrVvS7B_5tnMGLvfAc1HS-v9K2Zfv073kX-SKkZI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3081881682</pqid></control><display><type>article</type><title>Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective ‘ablate‐and‐resect’ study</title><source>MEDLINE</source><source>Wiley Blackwell Single Titles</source><creator>Peltier, Alexandre ; Velthoven, Roland ; Baudewyns, Arthur ; Assenmacher, Grégoire ; Lemort, Marc ; Lefebvre, Yolene ; Sirtaine, Nicolas ; Diamand, Romain</creator><creatorcontrib>Peltier, Alexandre ; Velthoven, Roland ; Baudewyns, Arthur ; Assenmacher, Grégoire ; Lemort, Marc ; Lefebvre, Yolene ; Sirtaine, Nicolas ; Diamand, Romain</creatorcontrib><description>Objective To assess histopathological outcomes, as well as feasibility and safety of targeted microwave ablation (TMA) via the Trinity® system (KOELIS, La Tronche, France). Patients and methods Prospective, single‐institution, interventional Phase IIa study with an ‘ablate‐and‐resect’ design. In all, 11 patients diagnosed with localised prostate cancer (PCa) underwent TMA via the Trinity system under conscious sedation in an outpatient setting using a single transrectal TATO® 18‐G antenna with different treatment regimens. Magnetic resonance imaging (MRI) and robot‐assisted radical prostatectomy (RARP) were conducted at 7 days and 1 month after TMA, respectively. Nine patients received RARP, and two patients chose to withdraw their consent following TMA. These men chose an active surveillance protocol upon confirmation of a low‐risk prostate cancer diagnosis. Functional outcomes and adverse events were evaluated at baseline and follow‐up visits using validated questionnaires. Prostate volumetry and confirmation of necrosis were carried out through MRI and whole‐mount histopathological examination. Results The TMA was successfully executed, and all patients were discharged on the same day. No severe adverse events (Common Terminology Criteria for Adverse Events Grade ≥3) were reported at the 7‐day and 1‐month follow‐up visits. Additionally, no declines were observed in urinary, sexual and ejaculation functional outcomes. T1‐weighted MRI revealed clear and well‐defined ablation zones. The RARP was executed without difficulty, particularly during the dissection of the posterior plane. As a result, no intraoperative complications were encountered. Histopathological assessment on surgical specimens confirmed the absence of viable cells, indicating complete necrosis of the ablative zone if a power intensity &gt;10 W was used during TMA. Ablation zone volumetry revealed no notable distinctions between the three‐dimensional segmentation of the virtual ablation zone at TMA (median volume: 2 mL) and MRI (median volume: 1.923 mL). Conversely, a significant reduction was noted in the surgical specimen (median volume: 0.221 mL). Conclusions Targeted microwave ablation via the Trinity system for localised PCa treatment proves to be a secure and feasible procedure, with complete necrosis evidence within the ablation zone on surgical specimens.</description><identifier>ISSN: 1464-4096</identifier><identifier>ISSN: 1464-410X</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/bju.16385</identifier><identifier>PMID: 38742416</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Ablation ; Ablation Techniques - methods ; Adverse events ; Aged ; Ejaculation ; Feasibility Studies ; Focal therapy ; Functional magnetic resonance imaging ; Humans ; Image processing ; Magnetic Resonance Imaging ; Male ; microwave ; Microwave ablation ; Microwaves - therapeutic use ; Middle Aged ; Necrosis ; Prospective Studies ; Prostate cancer ; Prostatectomy ; Prostatectomy - methods ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - surgery ; radical prostatectomy ; Robotic Surgical Procedures ; Terminology ; Treatment Outcome</subject><ispartof>BJU international, 2024-08, Vol.134 (2), p.258-267</ispartof><rights>2024 BJU International.</rights><rights>Copyright © 2024 BJU International</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3135-4e6324e699447b832142b8e4a4094206047a98aa88b4c491e324a555325ab64b3</cites><orcidid>0009-0008-0089-1030</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbju.16385$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbju.16385$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38742416$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peltier, Alexandre</creatorcontrib><creatorcontrib>Velthoven, Roland</creatorcontrib><creatorcontrib>Baudewyns, Arthur</creatorcontrib><creatorcontrib>Assenmacher, Grégoire</creatorcontrib><creatorcontrib>Lemort, Marc</creatorcontrib><creatorcontrib>Lefebvre, Yolene</creatorcontrib><creatorcontrib>Sirtaine, Nicolas</creatorcontrib><creatorcontrib>Diamand, Romain</creatorcontrib><title>Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective ‘ablate‐and‐resect’ study</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>Objective To assess histopathological outcomes, as well as feasibility and safety of targeted microwave ablation (TMA) via the Trinity® system (KOELIS, La Tronche, France). Patients and methods Prospective, single‐institution, interventional Phase IIa study with an ‘ablate‐and‐resect’ design. In all, 11 patients diagnosed with localised prostate cancer (PCa) underwent TMA via the Trinity system under conscious sedation in an outpatient setting using a single transrectal TATO® 18‐G antenna with different treatment regimens. Magnetic resonance imaging (MRI) and robot‐assisted radical prostatectomy (RARP) were conducted at 7 days and 1 month after TMA, respectively. Nine patients received RARP, and two patients chose to withdraw their consent following TMA. These men chose an active surveillance protocol upon confirmation of a low‐risk prostate cancer diagnosis. Functional outcomes and adverse events were evaluated at baseline and follow‐up visits using validated questionnaires. Prostate volumetry and confirmation of necrosis were carried out through MRI and whole‐mount histopathological examination. Results The TMA was successfully executed, and all patients were discharged on the same day. No severe adverse events (Common Terminology Criteria for Adverse Events Grade ≥3) were reported at the 7‐day and 1‐month follow‐up visits. Additionally, no declines were observed in urinary, sexual and ejaculation functional outcomes. T1‐weighted MRI revealed clear and well‐defined ablation zones. The RARP was executed without difficulty, particularly during the dissection of the posterior plane. As a result, no intraoperative complications were encountered. Histopathological assessment on surgical specimens confirmed the absence of viable cells, indicating complete necrosis of the ablative zone if a power intensity &gt;10 W was used during TMA. Ablation zone volumetry revealed no notable distinctions between the three‐dimensional segmentation of the virtual ablation zone at TMA (median volume: 2 mL) and MRI (median volume: 1.923 mL). Conversely, a significant reduction was noted in the surgical specimen (median volume: 0.221 mL). Conclusions Targeted microwave ablation via the Trinity system for localised PCa treatment proves to be a secure and feasible procedure, with complete necrosis evidence within the ablation zone on surgical specimens.</description><subject>Ablation</subject><subject>Ablation Techniques - methods</subject><subject>Adverse events</subject><subject>Aged</subject><subject>Ejaculation</subject><subject>Feasibility Studies</subject><subject>Focal therapy</subject><subject>Functional magnetic resonance imaging</subject><subject>Humans</subject><subject>Image processing</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>microwave</subject><subject>Microwave ablation</subject><subject>Microwaves - therapeutic use</subject><subject>Middle Aged</subject><subject>Necrosis</subject><subject>Prospective Studies</subject><subject>Prostate cancer</subject><subject>Prostatectomy</subject><subject>Prostatectomy - methods</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - surgery</subject><subject>radical prostatectomy</subject><subject>Robotic Surgical Procedures</subject><subject>Terminology</subject><subject>Treatment Outcome</subject><issn>1464-4096</issn><issn>1464-410X</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFOGzEQhi1URCD0wAuglXoJhwR7Pet4ubURtFRROZBIva3GmwnaaLMb7F1QbnmEHtvXy5N0SKAHpPowtjzf_JqZX4gzJQeKz6VbtANltE0OxLECA31Q8ueHt7dMTUechLCQkj9MciQ62g4hBmWORTlB_0ANzaJlkfv6GZ8oQldiU9RVNK99tPJ1aLChKMcqJx_1bu7uJ7c_rpW7uIpwl15R3hRct9383pXSdvMLqxlHT4Fz282fKDTtbH0qDudYBvr4enfF9OZ6MvrWH999vR19HvdzrXTSBzI65pCmAENndawgdpYAeRSIpZEwxNQiWusgh1QR05gkiY4TdAac7oreXpe7e2wpNNmyCDmVJVZUtyHTMgHL44Nm9NM7dFG3vuLumLLKWmVszNTFnuIVheBpnq18sUS_zpTMXizI2IJsZwGz56-KrVvS7B_5tnMGLvfAc1HS-v9K2Zfv073kX-SKkZI</recordid><startdate>202408</startdate><enddate>202408</enddate><creator>Peltier, Alexandre</creator><creator>Velthoven, Roland</creator><creator>Baudewyns, Arthur</creator><creator>Assenmacher, Grégoire</creator><creator>Lemort, Marc</creator><creator>Lefebvre, Yolene</creator><creator>Sirtaine, Nicolas</creator><creator>Diamand, Romain</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0008-0089-1030</orcidid></search><sort><creationdate>202408</creationdate><title>Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective ‘ablate‐and‐resect’ study</title><author>Peltier, Alexandre ; Velthoven, Roland ; Baudewyns, Arthur ; Assenmacher, Grégoire ; Lemort, Marc ; Lefebvre, Yolene ; Sirtaine, Nicolas ; Diamand, Romain</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3135-4e6324e699447b832142b8e4a4094206047a98aa88b4c491e324a555325ab64b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Ablation</topic><topic>Ablation Techniques - methods</topic><topic>Adverse events</topic><topic>Aged</topic><topic>Ejaculation</topic><topic>Feasibility Studies</topic><topic>Focal therapy</topic><topic>Functional magnetic resonance imaging</topic><topic>Humans</topic><topic>Image processing</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>microwave</topic><topic>Microwave ablation</topic><topic>Microwaves - therapeutic use</topic><topic>Middle Aged</topic><topic>Necrosis</topic><topic>Prospective Studies</topic><topic>Prostate cancer</topic><topic>Prostatectomy</topic><topic>Prostatectomy - methods</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - surgery</topic><topic>radical prostatectomy</topic><topic>Robotic Surgical Procedures</topic><topic>Terminology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peltier, Alexandre</creatorcontrib><creatorcontrib>Velthoven, Roland</creatorcontrib><creatorcontrib>Baudewyns, Arthur</creatorcontrib><creatorcontrib>Assenmacher, Grégoire</creatorcontrib><creatorcontrib>Lemort, Marc</creatorcontrib><creatorcontrib>Lefebvre, Yolene</creatorcontrib><creatorcontrib>Sirtaine, Nicolas</creatorcontrib><creatorcontrib>Diamand, Romain</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peltier, Alexandre</au><au>Velthoven, Roland</au><au>Baudewyns, Arthur</au><au>Assenmacher, Grégoire</au><au>Lemort, Marc</au><au>Lefebvre, Yolene</au><au>Sirtaine, Nicolas</au><au>Diamand, Romain</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective ‘ablate‐and‐resect’ study</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2024-08</date><risdate>2024</risdate><volume>134</volume><issue>2</issue><spage>258</spage><epage>267</epage><pages>258-267</pages><issn>1464-4096</issn><issn>1464-410X</issn><eissn>1464-410X</eissn><abstract>Objective To assess histopathological outcomes, as well as feasibility and safety of targeted microwave ablation (TMA) via the Trinity® system (KOELIS, La Tronche, France). Patients and methods Prospective, single‐institution, interventional Phase IIa study with an ‘ablate‐and‐resect’ design. In all, 11 patients diagnosed with localised prostate cancer (PCa) underwent TMA via the Trinity system under conscious sedation in an outpatient setting using a single transrectal TATO® 18‐G antenna with different treatment regimens. Magnetic resonance imaging (MRI) and robot‐assisted radical prostatectomy (RARP) were conducted at 7 days and 1 month after TMA, respectively. Nine patients received RARP, and two patients chose to withdraw their consent following TMA. These men chose an active surveillance protocol upon confirmation of a low‐risk prostate cancer diagnosis. Functional outcomes and adverse events were evaluated at baseline and follow‐up visits using validated questionnaires. Prostate volumetry and confirmation of necrosis were carried out through MRI and whole‐mount histopathological examination. Results The TMA was successfully executed, and all patients were discharged on the same day. No severe adverse events (Common Terminology Criteria for Adverse Events Grade ≥3) were reported at the 7‐day and 1‐month follow‐up visits. Additionally, no declines were observed in urinary, sexual and ejaculation functional outcomes. T1‐weighted MRI revealed clear and well‐defined ablation zones. The RARP was executed without difficulty, particularly during the dissection of the posterior plane. As a result, no intraoperative complications were encountered. Histopathological assessment on surgical specimens confirmed the absence of viable cells, indicating complete necrosis of the ablative zone if a power intensity &gt;10 W was used during TMA. Ablation zone volumetry revealed no notable distinctions between the three‐dimensional segmentation of the virtual ablation zone at TMA (median volume: 2 mL) and MRI (median volume: 1.923 mL). Conversely, a significant reduction was noted in the surgical specimen (median volume: 0.221 mL). Conclusions Targeted microwave ablation via the Trinity system for localised PCa treatment proves to be a secure and feasible procedure, with complete necrosis evidence within the ablation zone on surgical specimens.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38742416</pmid><doi>10.1111/bju.16385</doi><tpages>10</tpages><orcidid>https://orcid.org/0009-0008-0089-1030</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1464-4096
ispartof BJU international, 2024-08, Vol.134 (2), p.258-267
issn 1464-4096
1464-410X
1464-410X
language eng
recordid cdi_proquest_miscellaneous_3054841643
source MEDLINE; Wiley Blackwell Single Titles
subjects Ablation
Ablation Techniques - methods
Adverse events
Aged
Ejaculation
Feasibility Studies
Focal therapy
Functional magnetic resonance imaging
Humans
Image processing
Magnetic Resonance Imaging
Male
microwave
Microwave ablation
Microwaves - therapeutic use
Middle Aged
Necrosis
Prospective Studies
Prostate cancer
Prostatectomy
Prostatectomy - methods
Prostatic Neoplasms - pathology
Prostatic Neoplasms - surgery
radical prostatectomy
Robotic Surgical Procedures
Terminology
Treatment Outcome
title Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective ‘ablate‐and‐resect’ study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T22%3A56%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20microwave%20ablation%20for%20prostate%20cancer%20(FOSTINE1b):%20a%20prospective%20%E2%80%98ablate%E2%80%90and%E2%80%90resect%E2%80%99%20study&rft.jtitle=BJU%20international&rft.au=Peltier,%20Alexandre&rft.date=2024-08&rft.volume=134&rft.issue=2&rft.spage=258&rft.epage=267&rft.pages=258-267&rft.issn=1464-4096&rft.eissn=1464-410X&rft_id=info:doi/10.1111/bju.16385&rft_dat=%3Cproquest_cross%3E3081881682%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3081881682&rft_id=info:pmid/38742416&rfr_iscdi=true